A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs ASP 1707 (Primary) ; Leuprorelin
  • Indications Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 13 Jan 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 19 Aug 2014 Status changed from recruiting to active, no longer recruiting according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top